Candida
Mechanisms of ResistanceComparative Genomics of Serial Candida glabrata Isolates and the Rapid Acquisition of Echinocandin Resistance during TherapyThe opportunistic pathogen Candida glabrata shows a concerning increase in drug resistance. Here, we present the analysis of two serial bloodstream isolates, obtained 12 days apart.
SusceptibilityAPX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference MethodAPX001A is the active moiety of the first-in-class drug candidate APX001. So far, most susceptibility testing studies have examined ≤30 isolates/species, and only one used the EUCAST method.
Experimental TherapeuticsSignificantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive CandidiasisAPX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is significantly shorter in mice than in humans (1.4 to 2.75 h in mice versus 2 to 2.5 days in humans), making the exploration of efficacy in mouse models difficult.
- Clinical TherapeuticsEchinocandin Treatment of Candida albicans Biofilms Enhances Neutrophil Extracellular Trap Formation
The nosocomial pathogen Candida albicans forms biofilms on medical devices that persist in the face of antifungals and host defenses. Echinocandins, the most effective antibiofilm drugs, have recently been shown to augment the activity of neutrophils against biofilms through an unknown mechanism.
- Mechanisms of ResistanceUnderstanding Echinocandin Resistance in the Emerging Pathogen Candida auris
- Epidemiology and SurveillanceOvertreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study